CellAxia is a biotechnology startup that aims to pioneer advanced cell therapies for healthcare innovation. Founded in 2017, the company is dedicated to drug discovery, focusing on the development of cell treatment therapies. With its recent ¥700.00M Series B investment on 11 September 2020, CellAxia secured backing from a consortium of notable investors including Mitsubishi UFJ Capital, Mizuho Capital, Okasan Capital Partners, Miyako Capital, M3, and Fukuoka Financial Group.
As a bio-venture, CellAxia's primary focus is to bring advanced research in cell therapy into practical use, catering primarily to clients within the healthcare industry. The company operates at the intersection of biotechnology, health care, and health and wellness, positioning itself to make significant contributions to the evolving landscape of medical treatment and innovation in the years to come.
